Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification

Michael Weintraub, Gerald Ginsberg, E. Carol Stein, P. R. Sundaresan, Barbara Schuster, Patrick O'Connor, Louise M. Byrne

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We added phenylpropanolamine OROS (Acutrim; Ciba‐Geigy Corp.) or placebo to a physician‐managed behavior modification, mild caloric restriction, and exercise weight control program. One hundred six healthy, overweight (115% to 130% ideal body weight) women participated in this 14‐week double‐blind clinical trial. On average, the participants who took Acutrim lost significantly more weight (X̄ ± SE; 6.1 ± 0.6 kg; 8.0% ± 0.8%) than did those taking placebo (4.3 ± 0.7 kg; 5.5% ± 0.8%; P < 0.05). Those taking Acutrim continued to lose weight over the Christmas holiday, while the placebo group gained weight. Fifteen participants taking placebo withdrew, three because of adverse drug reactions (ADRs). Thirteen of 53 participants in the Acutrim group left the study, two because of ADRs. Dry mouth was the most frequent complaint from participants taking Acutrim. No serious cardiovascular effects occurred. Both complaints and the number of participants reporting ADRs decreased with continued dosing. We conclude that Acutrim is a safe, modestly effective adjunct to a physician‐managed, integrated weight control program. Clinical Pharmacology and Therapeutics (1986) 39, 501–509; doi:

Original languageEnglish (US)
Pages (from-to)501-509
Number of pages9
JournalClinical Pharmacology & Therapeutics
Volume39
Issue number5
DOIs
StatePublished - Jan 1 1986

Fingerprint

Phenylpropanolamine
Caloric Restriction
Behavior Therapy
Placebos
Weights and Measures
Drug-Related Side Effects and Adverse Reactions
Ideal Body Weight
Holidays
Clinical Pharmacology
Mouth
Clinical Trials
Exercise

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification. / Weintraub, Michael; Ginsberg, Gerald; Stein, E. Carol; Sundaresan, P. R.; Schuster, Barbara; O'Connor, Patrick; Byrne, Louise M.

In: Clinical Pharmacology & Therapeutics, Vol. 39, No. 5, 01.01.1986, p. 501-509.

Research output: Contribution to journalArticle

Weintraub, Michael ; Ginsberg, Gerald ; Stein, E. Carol ; Sundaresan, P. R. ; Schuster, Barbara ; O'Connor, Patrick ; Byrne, Louise M. / Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification. In: Clinical Pharmacology & Therapeutics. 1986 ; Vol. 39, No. 5. pp. 501-509.
@article{8ac6f5afb409462dbda00c8d028a06a3,
title = "Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification",
abstract = "We added phenylpropanolamine OROS (Acutrim; Ciba‐Geigy Corp.) or placebo to a physician‐managed behavior modification, mild caloric restriction, and exercise weight control program. One hundred six healthy, overweight (115{\%} to 130{\%} ideal body weight) women participated in this 14‐week double‐blind clinical trial. On average, the participants who took Acutrim lost significantly more weight (X̄ ± SE; 6.1 ± 0.6 kg; 8.0{\%} ± 0.8{\%}) than did those taking placebo (4.3 ± 0.7 kg; 5.5{\%} ± 0.8{\%}; P < 0.05). Those taking Acutrim continued to lose weight over the Christmas holiday, while the placebo group gained weight. Fifteen participants taking placebo withdrew, three because of adverse drug reactions (ADRs). Thirteen of 53 participants in the Acutrim group left the study, two because of ADRs. Dry mouth was the most frequent complaint from participants taking Acutrim. No serious cardiovascular effects occurred. Both complaints and the number of participants reporting ADRs decreased with continued dosing. We conclude that Acutrim is a safe, modestly effective adjunct to a physician‐managed, integrated weight control program. Clinical Pharmacology and Therapeutics (1986) 39, 501–509; doi:",
author = "Michael Weintraub and Gerald Ginsberg and Stein, {E. Carol} and Sundaresan, {P. R.} and Barbara Schuster and Patrick O'Connor and Byrne, {Louise M.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1038/clpt.1986.87",
language = "English (US)",
volume = "39",
pages = "501--509",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician‐managed behavior modification

AU - Weintraub, Michael

AU - Ginsberg, Gerald

AU - Stein, E. Carol

AU - Sundaresan, P. R.

AU - Schuster, Barbara

AU - O'Connor, Patrick

AU - Byrne, Louise M.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - We added phenylpropanolamine OROS (Acutrim; Ciba‐Geigy Corp.) or placebo to a physician‐managed behavior modification, mild caloric restriction, and exercise weight control program. One hundred six healthy, overweight (115% to 130% ideal body weight) women participated in this 14‐week double‐blind clinical trial. On average, the participants who took Acutrim lost significantly more weight (X̄ ± SE; 6.1 ± 0.6 kg; 8.0% ± 0.8%) than did those taking placebo (4.3 ± 0.7 kg; 5.5% ± 0.8%; P < 0.05). Those taking Acutrim continued to lose weight over the Christmas holiday, while the placebo group gained weight. Fifteen participants taking placebo withdrew, three because of adverse drug reactions (ADRs). Thirteen of 53 participants in the Acutrim group left the study, two because of ADRs. Dry mouth was the most frequent complaint from participants taking Acutrim. No serious cardiovascular effects occurred. Both complaints and the number of participants reporting ADRs decreased with continued dosing. We conclude that Acutrim is a safe, modestly effective adjunct to a physician‐managed, integrated weight control program. Clinical Pharmacology and Therapeutics (1986) 39, 501–509; doi:

AB - We added phenylpropanolamine OROS (Acutrim; Ciba‐Geigy Corp.) or placebo to a physician‐managed behavior modification, mild caloric restriction, and exercise weight control program. One hundred six healthy, overweight (115% to 130% ideal body weight) women participated in this 14‐week double‐blind clinical trial. On average, the participants who took Acutrim lost significantly more weight (X̄ ± SE; 6.1 ± 0.6 kg; 8.0% ± 0.8%) than did those taking placebo (4.3 ± 0.7 kg; 5.5% ± 0.8%; P < 0.05). Those taking Acutrim continued to lose weight over the Christmas holiday, while the placebo group gained weight. Fifteen participants taking placebo withdrew, three because of adverse drug reactions (ADRs). Thirteen of 53 participants in the Acutrim group left the study, two because of ADRs. Dry mouth was the most frequent complaint from participants taking Acutrim. No serious cardiovascular effects occurred. Both complaints and the number of participants reporting ADRs decreased with continued dosing. We conclude that Acutrim is a safe, modestly effective adjunct to a physician‐managed, integrated weight control program. Clinical Pharmacology and Therapeutics (1986) 39, 501–509; doi:

UR - http://www.scopus.com/inward/record.url?scp=0022612682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022612682&partnerID=8YFLogxK

U2 - 10.1038/clpt.1986.87

DO - 10.1038/clpt.1986.87

M3 - Article

VL - 39

SP - 501

EP - 509

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -